Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998

AIDS

Volumn 13, Issue 17, 1999, Pages

  Savès, Marianne ^a   Vandentorren, Stéhanie ^a   Daucourt, Valentin ^a   Marimoutou, Catherine ^a   Dupon, Michel ^a   Couzigou, Patrice ^a   Bernard, Noëlle ^a   Mercié, Patrick ^a   Dabis, François ^a,b,c,d,e,f  

^a Grp d'Epidemiol Clin du S   (France)

^b INSERM   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d HÔPITAL PELLEGRIN   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Adverse events; Hepatic cytolysis; Hepatitis c virus and hepatitis b virus co infections; Highly active antiretroviral therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; LIVER ENZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; COHORT ANALYSIS; CYTOLYSIS; FRANCE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032800972     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912030-00002     Document Type: Article

References (23)

1. Jacobson MA, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination nnliretroviral therapy. AIDS 1997, 12 (suppl A):S157-S163.
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
3. Palella FJ, Kathleen MD, Delaney M, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998, 338:853-860.
4. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals, lancet 1998, 352:314-316.
5. Fatkenheuer G, Thiesen A, Rockstroh J, et at. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
6. Piroth L, Grappin M, Waldner A, et al. Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients. Presse Med 1999, 28:381-387. {in French.1
7. Brau N, Leaf H, Wieczorek R, et al. Severe hepatitis in three AIDS patients treated with indinavir. lancet 1997, 349:924-925.
8. Spira R, Leroy V, Lacoste D, et al. Rapid change in the use of antiretroviral agents and improvement of a population of HIV-infected patients: France, 1995 to 1997.1 Acquit Immune Defic Syndr Hum Retmvirol 1998, 18:358-364.
9. Marimoutou C, Chêne G, Dabis F, et al. Human immunodeficiency virus and AIDS : hospital-based information system in Aquitaine, south-western France, 1985-1995. Presse Med 1997, 26:703-710. [in French.]
10. John M, Flexman J, French M. Hepatis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease ? AIDS1998, 12:2289-2293.
11. Saillour F, Dabis F, Dupon M, et al. Prevalence of hepatitis C virus antibody and serological markers of hepatitis B virus infection in the Aquitaine Cohort of HIV-infected patients, 1991-1994. BMJ 1996, 313:461-464.
12. Vento S, Garofano T, Renzini C, et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998, 12:116-117.
13. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenace of a cytotoxic T-lymphocyte response. Nature Medicine 1996, 2:1104-1108.
14. Carr A, Cooper D. Restoration of immunity to chronic hepatitis B infection in HIV-infected patients on protease inhibitor. lancet 1997, 349:995-996.
15. Rutschmann O, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998,177:783-785.
16. Zylberberg H, Chaix M, Rabian C. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998, 26:1104-1106.
17. Arribas J R, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998, 12:1722-1724.
18. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antirelroviral therapy. AIDS 1998, 12:1256.
19. Vergis E, Paterson DL, Singh N. Indinavir-associated hepatitis in patients with advanced HIV infection. Int I STDs and AIDS 1998,9:53.
20. Jeurissen FJF, Schneider MME, Borleffs JCC. Is the combination of hepatitis and indinavir potentially dangerous? AIDS 1998, 12:441-442.
21. Brau N, Leaf HL, Wieczorek RL, et al. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir. lancet 1997, 349:924-925.
22. Zylberberg H, Pialoux G, Carnot F, et al. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998, 27:1255-1258.
23. Inglesby T, Rai R, Astemborski J. A prospective, communitybased evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999, 29:590-592.